Connection

Prabhakar Baliga to Graft Rejection

Back to Details
This is a "connection" page, showing publications Prabhakar Baliga has written about Graft Rejection.
Prabhakar Baliga
Connection Strength
4.262
Graft Rejection
  1. Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients. Ann Transplant. 2018 Feb 16; 23:119-128.
    View in: PubMed
    Score: 0.460
  2. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017 09; 266(3):450-456.
    View in: PubMed
    Score: 0.446
  3. Improving transplant patient safety through pharmacist discharge medication reconciliation. Am J Transplant. 2013 Mar; 13(3):796-801.
    View in: PubMed
    Score: 0.323
  4. A critical analysis of racial difference with mycophenolate mofetil (MMF) dosing, clinical outcomes and adverse effects in pediatric kidney transplant patients. Clin Transplant. 2011 Jul-Aug; 25(4):534-40.
    View in: PubMed
    Score: 0.272
  5. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):40-7.
    View in: PubMed
    Score: 0.247
  6. Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population. Clin Transplant. 2019 10; 33(10):e13701.
    View in: PubMed
    Score: 0.128
  7. Long-standing diabetes mellitus and pancreas transplantation: An avenue to increase utilization of an ideal treatment modality. Clin Transplant. 2019 10; 33(10):e13695.
    View in: PubMed
    Score: 0.128
  8. Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant. 2019 01; 19(1):98-109.
    View in: PubMed
    Score: 0.119
  9. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017 12; 101(12):2931-2938.
    View in: PubMed
    Score: 0.113
  10. Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients. Pharmacotherapy. 2017 Jun; 37(6):692-699.
    View in: PubMed
    Score: 0.109
  11. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation. 2017 Jan; 101(1):157-165.
    View in: PubMed
    Score: 0.106
  12. The Impact of Health Care Appointment Non-Adherence on Graft Outcomes in Kidney Transplantation. Am J Nephrol. 2017; 45(1):91-98.
    View in: PubMed
    Score: 0.106
  13. Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. Am J Surg. 2017 Apr; 213(4):666-672.
    View in: PubMed
    Score: 0.105
  14. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. Clin Transplant. 2016 05; 30(5):528-33.
    View in: PubMed
    Score: 0.101
  15. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015 Jun; 35(6):569-77.
    View in: PubMed
    Score: 0.095
  16. Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: a retrospective analysis. Blood Press. 2015 Feb; 24(1):14-22.
    View in: PubMed
    Score: 0.090
  17. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. Am J Nephrol. 2014; 40(1):19-28.
    View in: PubMed
    Score: 0.089
  18. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014 May; 259(5):888-93.
    View in: PubMed
    Score: 0.088
  19. Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients. Ther Drug Monit. 2013 Dec; 35(6):753-9.
    View in: PubMed
    Score: 0.086
  20. Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation. Prog Transplant. 2013 Mar; 23(1):33-8.
    View in: PubMed
    Score: 0.082
  21. Pre-existing diabetes significantly increases the risk of graft failure and mortality following renal transplantation. Clin Transplant. 2013 Mar-Apr; 27(2):274-82.
    View in: PubMed
    Score: 0.081
  22. The impact of diabetes on ethnic disparities seen in kidney transplantation. Ethn Dis. 2013; 23(2):238-44.
    View in: PubMed
    Score: 0.081
  23. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients. Transplant Proc. 2012 Jun; 44(5):1323-8.
    View in: PubMed
    Score: 0.077
  24. Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression. Transplant Proc. 2009 Dec; 41(10):4131-7.
    View in: PubMed
    Score: 0.065
  25. Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int. 2010 May 01; 23(5):500-5.
    View in: PubMed
    Score: 0.065
  26. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005 Dec 15; 80(11):1633-5.
    View in: PubMed
    Score: 0.049
  27. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. Am J Transplant. 2003 Oct; 3(10):1278-88.
    View in: PubMed
    Score: 0.042
  28. The impact of race on metabolic, graft, and patient outcomes after pancreas transplantation. Am J Surg. 2022 04; 223(4):812-816.
    View in: PubMed
    Score: 0.036
  29. Cadaveric renal transplantation in African-Americans in South Carolina. Clin Transpl. 2001; 143-7.
    View in: PubMed
    Score: 0.035
  30. Differential effects of transferrin receptor blockade on the cellular mechanisms involved in graft rejection. Transpl Immunol. 1999 Sep; 7(3):131-9.
    View in: PubMed
    Score: 0.032
  31. Development and future deployment of a 5 years allograft survival model for kidney transplantation. Nephrology (Carlton). 2019 Aug; 24(8):855-862.
    View in: PubMed
    Score: 0.031
  32. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
    View in: PubMed
    Score: 0.028
  33. Effect of race on outcome after kidney and kidney-pancreas transplantation in type 1 diabetic patients. Diabetes Care. 1997 Aug; 20(8):1310-4.
    View in: PubMed
    Score: 0.028
  34. Morbid obesity and functional status as predictors of surgical complication after renal transplantation. Am J Surg. 2018 Apr; 215(4):663-668.
    View in: PubMed
    Score: 0.027
  35. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017 01 06; 12(1):131-139.
    View in: PubMed
    Score: 0.027
  36. Twenty years of evolving trends in racial disparities for adult kidney transplant recipients. Kidney Int. 2016 10; 90(4):878-87.
    View in: PubMed
    Score: 0.026
  37. Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients. Transplantation. 2016 07; 100(7):1550-7.
    View in: PubMed
    Score: 0.026
  38. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching. Exp Clin Transplant. 2017 Feb; 15(1):47-55.
    View in: PubMed
    Score: 0.026
  39. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant. 2016 Feb; 20(1):44-8.
    View in: PubMed
    Score: 0.025
  40. Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant. 2015 Aug; 19(5):555-62.
    View in: PubMed
    Score: 0.024
  41. Inflammatory biomarkers, glycemic variability, hypoglycemia, and renal transplant outcomes: results of a randomized controlled trial. Transplantation. 2014 Sep 27; 98(6):632-9.
    View in: PubMed
    Score: 0.023
  42. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C. Clin Transplant. 2014 Aug; 28(8):862-8.
    View in: PubMed
    Score: 0.022
  43. The impact of cardiovascular disease and risk factor treatment on ethnic disparities in kidney transplant. J Cardiovasc Pharmacol Ther. 2013 May; 18(3):243-50.
    View in: PubMed
    Score: 0.020
  44. Biochemical and histopathological correlation in liver transplant: the first 180 days. Hepatology. 1992 Sep; 16(3):688-93.
    View in: PubMed
    Score: 0.020
  45. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.019
  46. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation. 2004 Aug 27; 78(4):619-22.
    View in: PubMed
    Score: 0.011
  47. Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4.
    View in: PubMed
    Score: 0.009
  48. Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function. Clin Transplant. 1997 Aug; 11(4):294-8.
    View in: PubMed
    Score: 0.007
  49. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Transplant Proc. 1995 Oct; 27(5 Suppl 1):42-3.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.